{"disease":{"id":"nuclear-medicine-imaging-procedure","name":"Nuclear medicine imaging procedure","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"technetium-99mtc-nofetumomab-merpentan","indication_name":"Nuclear medicine imaging procedure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verluma","generic_name":"technetium (99mTc) nofetumomab merpentan","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"besilesomab","indication_name":"Nuclear medicine imaging procedure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scintimun","generic_name":"BESILESOMAB","company_name":"CIS bio international","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}